113 related articles for article (PubMed ID: 32693686)
21. Biological Heterogeneity of Chondrosarcoma: From (Epi) Genetics through Stemness and Deregulated Signaling to Immunophenotype.
Zając A; Król SK; Rutkowski P; Czarnecka AM
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33804155
[TBL] [Abstract][Full Text] [Related]
22. Novel Human-Derived
Schubert L; Le AT; Estrada-Bernal A; Doak AE; Yoo M; Ferrara SE; Goodspeed A; Kinose F; Rix U; Tan AC; Doebele RC
Mol Pharmacol; 2021 Jun; 99(6):435-447. PubMed ID: 33795352
[TBL] [Abstract][Full Text] [Related]
23. FGFR inhibitors in elderly patients with advanced biliary tract cancer: an unsolved issue.
Rizzo A; Ricci AD; Frega G; Di Federico A; Brandi G
Expert Rev Gastroenterol Hepatol; 2021 May; 15(5):567-574. PubMed ID: 33787429
[No Abstract] [Full Text] [Related]
24. An early look at selective RET inhibitor resistance: new challenges and opportunities.
Lin JJ; Gainor JF
Br J Cancer; 2021 May; 124(11):1757-1758. PubMed ID: 33758332
[TBL] [Abstract][Full Text] [Related]
25. Potential application of genomic profiling for the diagnosis and treatment of patients with sarcoma.
Xu L; Xie X; Shi X; Zhang P; Liu A; Wang J; Zhang B
Oncol Lett; 2021 May; 21(5):353. PubMed ID: 33747210
[TBL] [Abstract][Full Text] [Related]
26. Pancoast-Tobias Syndrome: A Unique Presentation of Lung Cancer.
Munir M; Jamil SB; Rehmani S; Borz-Baba C
Cureus; 2021 Feb; 13(2):e13112. PubMed ID: 33728131
[TBL] [Abstract][Full Text] [Related]
27. Tackling Drug Resistance in EGFR Exon 20 Insertion Mutant Lung Cancer.
Pacini L; Jenks AD; Vyse S; Wilding CP; Arthur A; Huang PH
Pharmgenomics Pers Med; 2021; 14():301-317. PubMed ID: 33727854
[TBL] [Abstract][Full Text] [Related]
28. Genetic differences between benign phyllodes tumors and fibroadenomas revealed through targeted next generation sequencing.
Ng CCY; Md Nasir ND; Loke BN; Tay TKY; Thike AA; Rajasegaran V; Liu W; Lee JY; Guan P; Lim AH; Chang KTE; Gudi MA; Madhukumar P; Tan BKT; Tan VKM; Wong CY; Yong WS; Ho GH; Ong KW; ; Yip GWC; Bay BH; Tan P; Teh BT; Tan PH
Mod Pathol; 2021 Jul; 34(7):1320-1332. PubMed ID: 33727697
[TBL] [Abstract][Full Text] [Related]
29. A CT-Based Radiomics Approach to Predict Nivolumab Response in Advanced Non-Small-Cell Lung Cancer.
Liu C; Gong J; Yu H; Liu Q; Wang S; Wang J
Front Oncol; 2021; 11():544339. PubMed ID: 33718125
[TBL] [Abstract][Full Text] [Related]
30. Do Molecular Profiles of Primary
Gomes-Lima CJ; Shobab L; Wu D; Ylli D; Bikas A; McCoy M; Feldman R; Lee W; Rao SN; Jensen K; Vasko V; Castro LC; Jonklaas J; Wartofsky L; Burman KD
Front Endocrinol (Lausanne); 2021; 12():623182. PubMed ID: 33716974
[TBL] [Abstract][Full Text] [Related]
31. Follicular T-cell lymphoma mimicking lymphocyte-rich classic Hodgkin lymphoma: a case report of a diagnostic pitfall.
Sakakibara A; Suzuki Y; Kato H; Yamamoto K; Sakata-Yanagimoto M; Ishikawa Y; Furukawa K; Shimada K; Kohno K; Nakamura S; Satou A; Kato S
J Clin Exp Hematop; 2021 Jun; 61(2):97-101. PubMed ID: 33716241
[TBL] [Abstract][Full Text] [Related]
32. A JAK/STAT-mediated inflammatory signaling cascade drives oncogenesis in AF10-rearranged AML.
Chen BR; Deshpande A; Barbosa K; Kleppe M; Lei X; Yeddula N; Vela PS; Campos AR; Wechsler-Reya RJ; Bagchi A; Meshinchi S; Eaves C; Jeremias I; Haferlach T; Frank DA; Ronai Z; Chanda S; Armstrong SA; Adams PD; Levine RL; Deshpande AJ
Blood; 2021 Jun; 137(24):3403-3415. PubMed ID: 33690798
[TBL] [Abstract][Full Text] [Related]
33. The evolving landscape of biomarker testing for non-small cell lung cancer in Europe.
Kerr KM; Bibeau F; Thunnissen E; Botling J; Ryška A; Wolf J; Öhrling K; Burdon P; Malapelle U; Büttner R
Lung Cancer; 2021 Apr; 154():161-175. PubMed ID: 33690091
[TBL] [Abstract][Full Text] [Related]
34. NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors.
Somwar R; Hofmann NE; Smith B; Odintsov I; Vojnic M; Linkov I; Tam A; Khodos I; Mattar MS; de Stanchina E; Flynn D; Ladanyi M; Drilon A; Shinde U; Davare MA
Commun Biol; 2020 Dec; 3(1):776. PubMed ID: 33328556
[TBL] [Abstract][Full Text] [Related]
35. Neuroblastoma patient-derived cultures are enriched for a mesenchymal gene signature and reflect individual drug response.
Hee E; Wong MK; Tan SH; Choo Z; Kuick CH; Ling S; Yong MH; Jain S; Lian DWQ; Ng EHQ; Yong YFL; Ren MH; Syed Sulaiman N; Low SYY; Chua YW; Syed MF; Lim TKH; Soh SY; Iyer P; Seng MSF; Lam JCM; Tan EEK; Chan MY; Tan AM; Chen Y; Chen Z; Chang KTE; Loh AHP
Cancer Sci; 2020 Oct; 111(10):3780-3792. PubMed ID: 32777141
[TBL] [Abstract][Full Text] [Related]
36. Selective type II TRK inhibitors overcome xDFG mutation mediated acquired resistance to the second-generation inhibitors selitrectinib and repotrectinib.
Xiang S; Lu X
Acta Pharm Sin B; 2024 Feb; 14(2):517-532. PubMed ID: 38322338
[TBL] [Abstract][Full Text] [Related]
37. NTRK Gene Fusions in Solid Tumors and TRK Inhibitors: A Systematic Review of Case Reports and Case Series.
Iannantuono GM; Riondino S; Sganga S; Rosenfeld R; Guerriero S; Carlucci M; Capotondi B; Torino F; Roselli M
J Pers Med; 2022 Nov; 12(11):. PubMed ID: 36579526
[TBL] [Abstract][Full Text] [Related]
38. NTRK Fusion in Non-Small Cell Lung Cancer: Diagnosis, Therapy, and TRK Inhibitor Resistance.
Liu F; Wei Y; Zhang H; Jiang J; Zhang P; Chu Q
Front Oncol; 2022; 12():864666. PubMed ID: 35372074
[TBL] [Abstract][Full Text] [Related]
39. Larotrectinib followed by selitrectinib in a novel
Goh XN; Seng MS; Loh AHP; Gupta A; Chang KTE; Iyer P
J Oncol Pharm Pract; 2021 Mar; 27(2):485-489. PubMed ID: 32693686
[TBL] [Abstract][Full Text] [Related]
40. The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas.
DuBois SG; Laetsch TW; Federman N; Turpin BK; Albert CM; Nagasubramanian R; Anderson ME; Davis JL; Qamoos HE; Reynolds ME; Cruickshank S; Cox MC; Hawkins DS; Mascarenhas L; Pappo AS
Cancer; 2018 Nov; 124(21):4241-4247. PubMed ID: 30204247
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
